Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22471283 | 0.83 | ADRB1 (0.56) | SLC6A2SLC6A4SLC6A3SIRT6ADRB1 | |
| SCHEMBL6606833 | 0.83 | SIRT6 (0.52) | SIRT6ADRB1MAPTKCNJ1KCNH2 | |
| Hydrochloric Acid SCHEMBL31005744 | 0.82 | ADRB1 (0.55) | SLC6A2SLC6A4SLC6A3SIRT6ADRB1 | |
| SCHEMBL22546974 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| SCHEMBL12006634 | 0.81 | MAPT (0.46) | SIRT6MAPT | |
| SCHEMBL791700 | 0.81 | MAPT (0.46) | SIRT6MAPT | |
| SCHEMBL12006635 | 0.81 | MAPT (0.46) | SIRT6MAPT | |
| SCHEMBL24478523 | 0.79 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| SCHEMBL27665380 | 0.79 | SIRT6 (0.54) | SIRT6ADRB1MAPTKCNJ1KCNH2 | |
| SCHEMBL23524638 | 0.79 | SIRT6 (0.56) | SIRT6ADRB1MAPTKCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | SLC6A2 4807/4885SLC6A4 4697/4885SLC6A3 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.